COVID-19 Unveils Social Media Might: Is Pharma Listening Hard Enough?
COVID-19 has generated a mind-boggling one billion-plus mentions on social media, unleashing unstructured big data rich in insights. Experts explain why pharma may well want to“listen in” more raptly to such conversations across therapy areas while shaping some aspects of business strategy.
You may also be interested in...
The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.
Dr Reddy’s combines forces with the Russian Direct Investment Fund for clinical trials and supply of Sputnik V in India, amid what it views as “very important” data points in early studies of the COVID-19 vaccine.